NCT07025330View on ClinicalTrials.gov

A Study of Efgartigimod in Patients With IgG4-Related Disease

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

March 1, 2028

Study Completion Date

June 1, 2028

Conditions

IgG4-related Disease

Interventions

DRUG

Efgartigimod

efgartigimod 1000 mg subcutaneous injection given once weekly

Trial Locations (1)

94304-2210

Stanford University, Palo Alto

All Listed Sponsors

lead

Stanford University

OTHER